Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Alzheimers Disease: early-phase trial registry
35 of 150 indexed Alzheimers Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #78 of 28,707 conditions by registered trial count.
150 US clinical trials · 35 currently recruiting · #78 of 28,707 conditions by registered trial count
Alzheimers Disease: 150 US clinical trials tracked, 35 recruiting.
Alzheimers Disease is the subject of 150 registered US clinical trials on ClinicalTrials.gov, 35 of them currently open to new participants. 25 are in Phase 3-4 (later-stage) and 76 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 8 of these trials.
Enrollment posture brief
Registry condition alzheimers-disease
OPEN 35 | RECR 23% | LATE 25 | EARLY 76 | RANK #78 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Diabetes Mellitus (23% recruiting · 210 trials)
Alzheimers Disease lists 35 open slots (23% of 150 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Alzheimers Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Alzheimers Disease is recruiting below its size-band peers.
35 of 150 indexed trials (23.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Alzheimers Disease trials is spread across many organizations.
Eli Lilly and Company accounts for 8 of 150 trials (5.3%). 90 distinct sponsors appear on at least one study for this condition label.
-
Typical Alzheimers Disease enrolment sits around 105 participants.
Median target enrolment is 105 among the 148 trials that report a genuine target (sentinel values excluded). 70 of those (47.3%) plan for fewer than 100 participants.
-
Alzheimers Disease research is mostly interventional.
123 interventional and 27 observational studies make up this index (82% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
150 total, page 3 of 3
Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease
Octapharma
NCT00812565
Safety Study of CTS21166 to Treat Alzheimer Disease
CoMentis
NCT00621010
A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's
Eli Lilly and Company
NCT01148498
Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease
Biogen
NCT01397539
Online Caregiver Psychoeducation and Support for Alzheimer's
US Department of Veterans Affairs
NCT00416078
Nefiracetam in the Treatment of Alzheimer's Disease
National Institute of Neurological Disorders and Stroke (NINDS)
NCT00001933
Safety Study of Nicotinamide to Treat Alzheimer's Disease
University of California, Irvine
NCT00580931
Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease
Eli Lilly and Company
NCT00244322
Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease
University of Colorado, Denver
NCT01409915
Distance Savvy: Testing Tele-Savvy, a Distance Dementia Family Caregiver Education Program
Emory University
NCT02300584
A Safety Study of LY2886721 Multiple Doses in Healthy Subjects
Eli Lilly and Company
NCT01227252
Cerebrospinal Fluid (CSF) Biomarkers Alzheimer's Disease (AD) and Non-AD Dementias
Duke University
NCT01730430
MRI of Alzheimer's Disease Imaging Amyloid Plaques in Persons With and Without Memory Problems
National Institute of Neurological Disorders and Stroke (NINDS)
NCT00413621
Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease
Targacept
NCT01254448
Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)
Wake Forest University Health Sciences
NCT01595646
A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants
Hoffmann-La Roche
NCT04023994
Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease
Bristol-Myers Squibb
NCT00901498
Tau Imaging in Professional Fighters
Avid Radiopharmaceuticals
NCT02278354
Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia
Intra-Cellular Therapies
NCT02078310
BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects
Tetra Discovery Partners
NCT02648672
Memory and Insulin in Early Alzheimer's Disease
Jeff Burns, MD
NCT00581867
Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls
Molecular NeuroImaging
NCT00448799
A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)
Avid Radiopharmaceuticals
NCT01503944
A Safety and Tolerability Study of ABT-126 in Elderly
Abbott
NCT00867399
Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET
University of Utah
NCT01202994
A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers
Avid Radiopharmaceuticals
NCT01565343
A Study to Evaluate the Effect of Heat Application on the Delivery Profile of Corplex™ Donepezil Transdermal Delivery System (TDS)
Corium
NCT03438604
Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease
Stephen M. Strittmatter
NCT01864655
Wii-fit for Activity, Balance and Gait in Assisted Living
University of Nebraska
NCT01000038
A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function
Pfizer
NCT00824590
Effect of Insulin Sensitizer Metformin on AD Biomarkers
University of Pennsylvania
NCT01965756
Creatine to Augment Bioenergetics in Alzheimer's
University of Kansas Medical Center
NCT05383833
A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)
Pfizer
NCT00988624
Paired Integrative Home Exercise for Seniors With Dementia and Their Caregivers (PairedPLIE)
University of California, San Francisco
NCT02403752
Bexarotene Amyloid Treatment for Alzheimer's Disease
The Cleveland Clinic
NCT01782742
"Healthy Actions and Lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia Program"
Alzheimer's Disease Cooperative Study (ADCS)
NCT05350410
In Vivo Imaging of Therapeutic Electric Current Flow
University of Florida
NCT02453763
Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)
Wyeth is now a wholly owned subsidiary of Pfizer
NCT00151333
A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease
Pfizer
NCT00988598
Using a Wireless Controller to Deliver a Lighting Intervention to Persons With Dementia
Icahn School of Medicine at Mount Sinai
NCT05519137
A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
Pfizer
NCT00827034
A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects
ReXceptor
NCT02061878
Down Syndrome Biomarker Initiative (DSBI)
Michael Rafii
NCT02141971
Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.
HealthPartners Institute
NCT01436045
CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
Sangamo Therapeutics
NCT00087789
Oxaloacetate Pharmacokinetics and Safety
Russell Swerdlow, MD
NCT02063308
Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs.
Molecular NeuroImaging
NCT01859767
Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)
Johns Hopkins University
NCT01609348
Development and Decline of Brain and Cognition Through the Life Span
National Institute of Mental Health (NIMH)
NCT00880451
Gene-Environment Interactions in Alzheimer's Disease
US Department of Veterans Affairs
NCT00018473
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 37 |
| Phase 2 | 39 |
| Phase 3 | 25 |
Top Sponsors
Named interventions
Most-linked intervention names on Alzheimers Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Alzheimers Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Alzheimers Disease page
150 registered trials, 35 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 35 Alzheimers Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Alzheimers Disease trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Alzheimers Disease condition card totals 150 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.